This position will have the opportunity to work directly on novel antibody-drug conjugates in hematologic malignancies and/or solid tumors. Reporting to a Global Development Operations Leader within Clinical Project Management, the successful candidate will function as a scientific and medical resource within the clinical development operations department at Seattle Genetics, and as a clinical scientist fellow for ongoing clinical trials in oncology.
The fellow will support ADCETRIS® (brentuximab vedotin), an antibody-drug conjugate (ADC) directed to the CD30 surface antigen on cells using Seattle Genetics' proprietary ADC technology. The fellow will also support Seattle Genetics’ pipeline programs, including late-stage agents enfortumab vedotin and tucatinib.
Contribute to the execution of clinical trials through work within the Clinical Trials Management, Clinical Project Management and Data Management teams
Contribute to the development of clinical protocols and amendments, investigator brochures, and clinical study reports
Contribute to the strategic development of early and late stage clinical programs
Lead clinical study teams and provide appropriate scientific oversight for ongoing clinical studies
Evaluation of safety, pharmacology, and efficacy data from ongoing and completed studies
Prepare presentations for Investigators’, Advisory Boards and Steering Committee meetings
Conduct literature reviews and prepare summaries to support clinical development programs
Scientific and medical resource for design and interpretation of clinical and preclinical programs to support existing and new development candidates
We are looking for someone who:
Demonstrates a passion for helping patients with cancer and for the science of oncology
Has a strong leadership presence with an ability to work effectively with other clinical and scientific leaders
Has a collaborative style with internal company leadership, external development partners and investigators/medical professionals
Is a team player, works well in a team environment both as a leader and a key contributor
Has a global perspective and mindset, with the ability to work effectively with colleagues from myriad cultures, backgrounds and geographies
Clinical oncology experience; 1-2 years’ industry experience in oncology drug development preferred
Seattle Genetics is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, age, gender identity, sexual orientation, color, religion, sex, marital status, national origin, protected veteran status, disability status, or any other status protected by federal, state, or local law.
Application deadline is Wednesday, November 27th, 2019.
Letters of Recommendation are not required with application and are only required upon request.
Internal Number: 2019-627
About Seattle Genetics
Seattle Genetics is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) uses the company’s industry-leading antibody-drug conjugate (ADC) technology and is approved for the treatment of multiple CD30-expressing lymphomas.
Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer use our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.